Overview
The BPC-157 + TB-500 Blend adds two widely researched synthetic peptides in an equal ratio, i.e., 1:1 (5mg BPC-157 + 5mg TB-500 per vial). BPC-157 is a stable 15-amino-acid fragment obtained from the protein of human gastric juice, while TB-500 is a synthetic variant of the active domain of Thymosin Beta-4.
The synergistic effects of this combination on tissue repair, angiogenesis, cell migration, inflammation modulation, and regenerative biology are being researched in preclinical models. Each vial is delivered as a clean and lyophilized powder made in the USA that is ≥99% pure (HPLC-verified).
The pre-mixed format makedreconstitution simple, and supports efficient dosing in in vitro assays, cell culture, or animal injury models. This blend is used
exclusively for in vitro and in vivo laboratory research, and it is
not for human consumption, therapeutic use, veterinary application, or any non-research purpose.
For research use only. Strictly not for human consumption.
Biochemical Characteristics
BPC-157
-
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
-
Molecular formula: C₆₂H₉₈N₁₆O₂₂
-
Molecular weight: 1419.55 Da
- Stable in gastric juice; high resistance to enzymatic degradation
TB-500 (Thymosin Beta-4 fragment)
-
Active domain: Ac-LKKTETQ
-
Molecular formula: C₃₈H₆₈N₁₀O₁₄
-
Molecular weight: ≈889 Da
- Regulates actin polymerization and cytoskeletal dynamics
The blend is provided as a single lyophilized acetate salt powder. The 5mg/5mg ratio helps the researchers to find out an additive or synergistic relation between gastric-derived cytoprotection and actin-binding repair pathways.
Research Application
In preclinical studies, the BPC-157 + TB-500 combination is used to:
- Accelerate the healing of soft musculoskeletal tissues, for example, ligaments, muscles, and tendons.
- To study the activity of fibroblasts, deposition of collagen, and angiogenesis.
- Model reduction of edema and inflammation in ischemia-reperfusion or injury settings
- To see the formation of granulation tissue, closure of the wound, and biomechanical healing.
- To study the comparison of systemic and localized effects in models of severe lesions or tendon-to-bone integration.
- Function as a helpful tool for peptide-mediated cytoprotection, sports medicine models, and regenerative biology.
Comparative research and continuous dosing are supported by the pre-blended vial without the need for customized reconstitutions.
Mechanism Overview
BPC-157 increases growth factors (VEGF, FGF), FAK-paxillin signaling, and also changes the pathways of nitric oxide. While promoting angiogenesis, collagen organization, and the balance of anti-inflammatory cytokines, it keeps endothelial integrity.
Actin monomers are attached by TB-500, which also sequesters G-actin and promotes F-actin assembly. While promoting angiogenesis and decreasing inflammation through a number of mechanisms, it supports cell migration, differentiation, and cytoskeletal remodeling.
Together, these two ( TB-500 and BPC-157) improve motility, structural reorganization, growth factor,s and cytoprotection. Preclinical evidence suggests that fibroblast recruitment, vascularization, and tissue remodeling work together to improve functional recovery in injury models.
Preclinical Research Summary
Preclinical research demonstrates that BPC-157 enhances tendon, ligament, and muscle healing, specifically in rodent models. In Achilles transection and ligament injury models, it counteracts corticosteroid impairment, elevates collagen deposition, and increases biomechanical strength. TB-500 supports migration of cells, angiogenesis, and actin dynamics in wound and soft-tissue restoration.
In animal research, combined use shows improved results:
- Quicker formation of granulation tissue and wound closure
- Decreased edema and inflammation
- Better tendon-to-bone integration and ligament tensile load
- Systemic effects on the protection of distant organs, such as the liver and kidney in ischemia-reperfusion.
Systematic reviews show that more than 35 preclinical studies regularly produced positive histological and functional results, with no toxicity found in safety evaluations. The mixture is being studied for musculoskeletal regeneration, but the human data is still not enough.
Form and Analytical Testing
-
Form: Sterile, lyophilized powder blend (5mg BPC-157 + 5mg TB-500)
-
Purity: ≥99% (HPLC for each peptide)
-
Identity: Confirmed by mass spectrometry
-
Endotoxin: <0.1 EU/μg
-
Solubility: Excellent in bacteriostatic water
-
Appearance: White to off-white cake
-
Storage (unopened): 2–8°C, protected from light and moisture
-
Reconstitution: Use sterile bacteriostatic water under aseptic conditions
-
Stability: Stable 24–36 months refrigerated when sealed; reconstituted stable 4–6 weeks at 2–8°C (avoid repeated freeze-thaw)
All batches undergo third-party analytical testing for purity, identity, and contaminants.
Referenced Citations
- Sikiric P, et al. (2018). Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function. Pharmaceuticals.
- Chang CH, et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules.
doi:10.3390/molecules191119066.
- Vasireddi N, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. PMC12313605.
- Krivic A, et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing. Journal of Orthopaedic Research. doi:10.1002/jor.20109.
- Malinda KM, et al. (1999). Thymosin β4 accelerates wound healing. Journal of Investigative Dermatology.
RUO Disclaimer
The BPC-157 + TB-500 Blend (5mg/5mg) is an investigational research compound intended
solely for in vitro laboratory research and in vivo animal studies. It is
not approved by the FDA, EMA, or any regulatory authority for human therapeutic use, diagnosis, treatment, or supplementation.
It is classified as a research chemical (WADA S0 non-approved substances category), and preclinical findings do not predict human outcomes; no claims are made regarding safety or efficacy in humans.
Products may carry risks, including immunogenicity or impurities, if mishandled, it should be handled only in qualified research facilities with institutional biosafety oversight.
All sales are for laboratory research use only;
not for human or veterinary consumption.
